Clinical trials: Pruritis
Vulvar Lichen Sclerosus
The CO2RE® System for Vulvar Lichen Sclerosus
Subjects with vulvar lichen sclerosus (VLS) will undergo fractional carbon dioxide (CO2) laser treatment to the vulvar area. Subjects will be evaluated for changes in clinical signs and architectural changes associated with VLS…
- Trial name
- NCT04148651
- Testing
- The CO2RE® System
- Where
- 4 sites in United States
- Volunteers
- 14 people
- Sponsor
- Candela Corporation
Pruritus
Linerixibat and Obeticholic Acid Drug Interaction Study in Healthy Adult Participants
This study aims to investigate the effect of linerixibat on plasma concentrations of obeticholic acid (OCA) and its conjugates in healthy adult participants to inform the potential for drug interaction with coadministration of…
- Trial name
- NCT05133830
- Testing
- Obeticholic acid, Linerixibat
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Rhinitis, Allergic, Seasonal, Rhinitis, Allergic, Perennial
Observation of Use of Claritin (Loratadine) Tablet, RediTabs, and Dry Syrup in Children (Study P05834)(COMPLETED)
The purpose of this study is to collect information on unexpected adverse reactions (ADRs), how often ADRs occur, and factors that can affect the safety and effectiveness of Claritin (loratadine) when used in children.
- Conditions
- Rhinitis, Allergic, Seasonal, Rhinitis, Allergic, Perennial, Urticaria, Pruritus
- Trial name
- NCT00762983
- Testing
- loratadine
- Volunteers
- 1,003 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Pruritus of Unknown Origin
A Study to Evaluate Efficacy, Safety, and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)
The purpose of this phase 3 study is to establish the efficacy, safety and tolerability of remibrutinib in adult participants with severe chronic pruritus of unknown origin (CPUO).
- Trial name
- NCT07811869
- Testing
- Remibrutinib
- Where
- 10 sites in United States, Canada
- Volunteers
- 180 people
- Sponsor
- Novartis Pharmaceuticals
Tinea Pedis
Efficacy and Safety of LAS41003 in the Treatment of Inflammatory Tinea Pedis
The aim of this study is to determine the efficacy and safety of a topical application of the combinational cream LAS41003 compared to application of its mono-substances after once daily treatment in patients with inflammatory…
- Trial name
- NCT01096472
- Testing
- LAS41003, LAS189961, LAS189962
- Where
- 2 sites in Germany
- Volunteers
- 120 people
- Sponsor
- Almirall, S.A.
Chronic Kidney Disease-associated Pruritus
Cross-sectional Study to Assess Prevalence and Burden of CKD-associated Pruritus in Haemodialysis Patients
Vifor International Inc. is seeking real-world evidence (RWE) to better understand the epidemiology, patient characteristics, and management of CKD-aP in the real-world clinical setting.
- Trial name
- ReliefCensus (NCT05524467)
- Where
- 94 sites in Germany, Italy and 5 more
- Volunteers
- 3,100 people
- Sponsor
- Vifor (International) Inc.
Primary Biliary Cholangitis, PBC
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis
The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Biliary Cholangitis (PBC), and to assess the possible…
- Trial name
- VANTAGE (NCT05050136)
- Testing
- Volixibat
- Where
- 130 sites in United States, Argentina and 13 more
- Volunteers
- 333 people
- Sponsor
- Mirum Pharmaceuticals, Inc.
Chronic Inducible Urticaria
Study of Efficacy and Safety of Ligelizumab in Adolescents and Adults With Chronic Inducible Urticaria Who Remain Symptomatic Despite Treatment With H1- Antihistamines
This was a placebo controlled, phase 3 study designed to evaluate the efficacy and safety of ligelizumab in participants with chronic inducible urticaria who are inadequately controlled with H1-antihistamines
- Trial name
- PEARL-PROVOKE (NCT05024058)
- Testing
- Ligelizumab
- Where
- 24 sites in United States, Australia and 7 more
- Volunteers
- 39 people
- Sponsor
- Novartis Pharmaceuticals
Pruritus
Fexofenadine in Pruritic Skin Disease
Primary objective: To compare the efficacy and safety profile of Fexofenadine 180mg tablets plus prednicarbate(2.5mg/g) vs prednicarbate(2.5mg/g) alone in the treatment of pruritic skin disease Secondary objective: To evaluate…
- Trial name
- NCT00261079
- Testing
- Fexofenadine
- Where
- South Korea
- Volunteers
- 435 people
- Sponsor
- Handok Inc.
Chronic Pruritus of Unknown Origin
A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)
The purpose of this phase 3 study is to establish the efficacy, safety and tolerability of remibrutinib in adult participants with severe chronic pruritus of unknown origin (CPUO).
- Trial name
- NCT07700056
- Testing
- Remibrutinib
- Where
- 17 sites in United States, Argentina and 3 more
- Volunteers
- 180 people
- Sponsor
- Novartis Pharmaceuticals
Prurigo Nodularis, Nodularis Prurigo
Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis
The primary objective of the study is to evaluate the overall safety of nalbuphine HCL ER tablets during a treatment period of up to 50 weeks.
- Conditions
- Prurigo Nodularis, Nodularis Prurigo, Prurigo
- Trial name
- NCT02174432
- Testing
- nalbuphine HCl ER
- Where
- Germany
- Volunteers
- 36 people
- Sponsor
- Trevi Therapeutics
Pruritus
A Clinical Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of HSK21542 Injection in Liver Disease Subjects With Pruritus
This study is a multi-center, randomized, double-blind, placebo-controlled study. About 90 liver disease subjects with moderate or above pruritus are planned to be enrolled.
- Trial name
- NCT04999787
- Testing
- HSK21542
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Perennial Allergic Rhinitis
Efficacy Study for the Symptomatic Treatment of Perennial Allergic Rhinitis With a 1 Year Safety Extension
Double-blind phase: The objective of the study was to evaluate the efficacy and safety of Bilastine 20 mg, compared to Cetirizine and placebo for the treatment of perennial allergic rhinitis.
- Trial name
- NCT01127620
- Testing
- Bilastine, Cetirizine
- Volunteers
- 650 people
- Sponsor
- Faes Farma, S.A.
Pregnancy Related, Atopic Dermatitis
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis
This study is to assess infant outcomes of women with AD who were exposed to ruxolitinib cream during pregnancy compared with a control cohort of women with AD who were exposed to a topical corticosteroid (TCS) during pregnancy.
- Trial name
- NCT06627335
- Testing
- Ruxolitinib Cream, TCS
- Where
- United States
- Volunteers
- 5,621 people
- Sponsor
- Incyte Corporation
Chronic Spontaneous Urticaria
A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.
The purpose of the study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the treatment of chronic spontaneous urticaria (CSU) that is not effectively treated by antihistamines which are…
- Trial name
- NCT07219615
- Testing
- Ritlecitinib 50 mg, Ritlecitinib 100 mg
- Where
- 77 sites in United States, Bulgaria and 8 more
- Volunteers
- 200 people
- Sponsor
- Pfizer
Uremic Pruritus
CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
This is a multicenter, open-label study to evaluate the safety and effectiveness of intravenous (IV) CR845 at a dose of 0.5 mcg/kg administered after each dialysis session. The study includes an up to 12-week Treatment Period.
- Trial name
- NCT03998163
- Testing
- CR845 0.5 mcg/kg
- Where
- 47 sites in United States, Czechia and 2 more
- Volunteers
- 222 people
- Sponsor
- Cara Therapeutics, Inc.
Seasonal Allergic Rhinitis
A Randomized, Double-blind, Placebo-controlled Study on the Effect of CVT-E002 in Patients With Seasonal Allergic Rhinitis
You are being asked to take part in a research study of COLD-fX, a product designed to boost the immune system. COLD-fX is an extract from the roots of North American ginseng and it may offer some benefit to people with seasonal…
- Trial name
- NCT00726401
- Testing
- COLD-fX
- Where
- 4 sites in Canada
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Afexa Life Sciences Inc
Progressive Familial Intrahepatic Cholestasis (PFIC)
Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 (Maralixibat) in the Treatment of Cholestatic Liver Disease in Patients With Progressive Familial Intrahepatic Cholestasis
This is an open label study in children with Progressive Familial Intrahepatic Cholestasis (PFIC) designed to evaluate the safety and efficacy of LUM001, also known as Maralixibat (MRX).
- Trial name
- INDIGO (NCT02057718)
- Testing
- LUM001 (Maralixibat)
- Where
- 10 sites in United States, France and 2 more
- Volunteers
- 33 people
- Sponsor
- Mirum Pharmaceuticals, Inc.
Chronic Kidney Disease-associated Pruritus
The MC2-25 Cream in Subjects wITh CHronic KIdNEy Disease-aSsociated prurituS (ITCHINESS) Trial
The purpose of this study is to access the efficacy and safety of MC2-25 cream and MC2-25 vehicle for treatment of chronic kidney disease associated pruritus (CKD)-aP).
- Trial name
- ITCHINESS (NCT05482698)
- Testing
- MC2-25 cream, MC2-25 vehicle
- Where
- United Kingdom
- Volunteers
- 111 people
- Sponsor
- MC2 Therapeutics
Uremic Pruritus in Hemodialysis Patients
A Study of SK-1405 in Hemodialysis Patients With Uremic Pruritus
The purpose of this study is to evaluate the efficacy, safety and dose response of SK-1405 for the treatment of subjects with uremic pruritus receiving hemodialysis, during 2 weeks of treatment.
- Trial name
- NCT03218501
- Testing
- SK-1405 high dose, SK-1405 low dose
- Where
- Japan
- Volunteers
- 269 people
- Sponsor
- Sanwa Kagaku Kenkyusho Co., Ltd.